RetinalGenix Technologies (RTGN) R&D In Process (2022)
RetinalGenix Technologies' (RTGN) quarterly R&D In Process came in at $2.0 million in Q3 2022.
RetinalGenix Technologies (RTGN) R&D In Process (2022) Analysis & Trends
RetinalGenix Technologies has disclosed R&D In Process across 1 years of filings, most recently posting $2.0 million for Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | - |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | - |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | - |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | - |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | RetinalGenix Technologies | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.03 Mn |